

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb

RRID:AB_331795

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4407, RRID:AB_331795

Antibody Information

URL: http://antibodyregistry.org/AB_331795

Proper Citation: Cell Signaling Technology Cat# 4407, RRID:AB_331795

Target Antigen: Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P. Consolidation on 10/2018: AB_10078338, AB_10079350, AB_331795, AB_331796. Info: Used By NYUIHC-661. Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb

Description: This monoclonal targets Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_331795

Vendor: Cell Signaling Technology

Catalog Number: 4407

Record Creation Time: 20250819T220941+0000

Record Last Update: 20250820T011817+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Dacheux MA, et al. (2025) BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling. bioRxiv : the preprint server for biology.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell reports. Medicine, 6(8), 102253.

Mudumbi KC, et al. (2024) Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranes. Cell reports, 43(1), 113603.

Zhang Q, et al. (2024) Endorepellin downregulation promotes angiogenesis after experimental traumatic brain injury. Neural regeneration research, 19(5), 1092.

Song WM, et al. (2023) Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. iScience, 26(2), 106064.

Yamada K, et al. (2023) Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding. Nature communications, 14(1), 8301.

Vallés-Martí A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. Cell reports, 42(6), 112581.

Rizzo S, et al. (2023) Promoting the activity of a receptor tyrosine phosphatase with a novel pH-responsive transmembrane agonist inhibits cancer-associated phenotypes. Protein science : a publication of the Protein Society, 32(9), e4742.

Shao WQ, et al. (2022) Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. *Cell reports*, 39(3), 110712.

Shi Z, et al. (2022) Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas. *Molecular cell*, 82(20), 3919.

Zhang R, et al. (2022) Cellular signals converge at the NOX2-SHP-2 axis to induce reductive carboxylation in cancer cells. *Cell chemical biology*, 29(7), 1200.

Celen C, et al. (2022) Arid1a loss potentiates pancreatic β -cell regeneration through activation of EGF signaling. *Cell reports*, 41(5), 111581.

Bosse KR, et al. (2022) Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. *Cancer discovery*, 12(12), 2800.

Wu Q, et al. (2022) EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. *Cancer discovery*, 12(5), 1378.

Chava S, et al. (2022) Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis. *iScience*, 25(5), 104211.

Kizilbash SH, et al. (2021) In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. *Molecular cancer therapeutics*, 20(6), 1009.

Hua TNM, et al. (2020) Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients. *Experimental & molecular medicine*, 52(4), 629.

Vaishnavi A, et al. (2020) Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. *Cell reports*, 32(5), 107994.

Bell ES, et al. (2019) LC3C-Mediated Autophagy Selectively Regulates the Met RTK and HGF-Stimulated Migration and Invasion. *Cell reports*, 29(12), 4053.

Pascolutti R, et al. (2019) Molecularly Distinct Clathrin-Coated Pits Differentially Impact EGFR Fate and Signaling. *Cell reports*, 27(10), 3049.